Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An acute myeloid leukemia arising de novo and not as a result of treatment. It is characterized by the presence of myelodysplastic features in at least 50% of the cells of at least two hematopoietic cell lines. Patients often present with severe cytopenia.
Biomarker and diagnostic research for acute myeloid leukemia with multilineage dysplasia has been reported in the published literature.
4 clinical trials registered. Interventions under study include drug therapy, other interventions, and procedural interventions. Pipeline includes 1 PHASE2, 1 PHASE1, 1 NA. Research is primarily sponsored by academic and government institutions.
27 publications have been identified in PubMed for acute myeloid leukemia with multilineage dysplasia. Research spans Review / Meta-Analysis (30%), Case Report / Case Series (19%), and Diagnostic / Biomarker (15%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 8 |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 8:44 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about acute myeloid leukemia with multilineage dysplasia
30%
Patient case studies | 5 | 19% |
Testing and diagnosis research | 4 | 15% |
Laboratory research | 4 | 15% |
Disease patterns and progression | 3 | 11% |
Clinical study results | 2 | 7% |
Other research | 1 | 4% |
Matsukawa T (2026). [PMID: 41666291](https://pubmed.ncbi.nlm.nih.gov/41666291/). *Hematology*. [Epidemiology / Natural History]
Wang N (2026). [PMID: 41855694](https://pubmed.ncbi.nlm.nih.gov/41855694/). *Leuk Res*. [Review / Meta-Analysis]
Cebeci S (2026). [PMID: 41904024](https://pubmed.ncbi.nlm.nih.gov/41904024/). *Clin Lymphoma Myeloma Leuk*. [Epidemiology / Natural History]
Kannan N (2026). [PMID: 41819800](https://pubmed.ncbi.nlm.nih.gov/41819800/). *J Clin Pathol*. [Clinical Trial Publication]
Meng F (2026). [PMID: 41711916](https://pubmed.ncbi.nlm.nih.gov/41711916/). *Ann Hematol*. [Review / Meta-Analysis]
Attardi E (2026). [PMID: 41785326](https://pubmed.ncbi.nlm.nih.gov/41785326/). *Blood Adv*. [Basic Science / Preclinical]
Bill M (2026). [PMID: 41145671](https://pubmed.ncbi.nlm.nih.gov/41145671/). *Leukemia*. [Diagnostic / Biomarker]
Koorse Germans S (2026). [PMID: 41720165](https://pubmed.ncbi.nlm.nih.gov/41720165/). *Hum Pathol*. [Review / Meta-Analysis]
Wei Y (2026). [PMID: 41732866](https://pubmed.ncbi.nlm.nih.gov/41732866/). *Hematol Oncol*. [Basic Science / Preclinical]
Saft L (2026). [PMID: 41948832](https://pubmed.ncbi.nlm.nih.gov/41948832/). *Am J Clin Pathol*. [Other]
AI-curated news mentioning acute myeloid leukemia with multilineage dysplasia
Updated Apr 13, 2026
A recent study published in PubMed explores the genetic underpinnings of acute myeloid leukemia with myelodysplasia-related features, specifically focusing on the del(5q) deletion and the amplification of the FLI1 gene. This research could provide insights into targeted therapies for affected patients.